伊特卡赛肽(商品名为Parsabiv~(TM))是安进公司开发的新型二代拟钙剂,主要用于治疗慢性肾病继发性甲状旁腺机能亢进。伊特卡赛肽通过直接与钙感应受体结合来降低血钙浓度,还可以降低甲状旁腺素的水平。欧盟于2016年11月批准注射用伊特卡赛肽用于慢性肾病继发性甲状旁腺机能亢进的透析患者。介绍该药的药理作用、药动学、临床试验及不良反应研究概况。 Itacustine (trade name Parsabiv TM) is a new type of second-generation calcimimetic developed by Amgen. It is mainly used for the treatment of secondary hyperparathyroidism of chronic kidney disease. It is also possible to reduce the level of parathyroid hormone by reducing the blood calcium concentration by directly binding to the calcium sensing receptor. In November 2016, the European Union approved the use of iticarbazide for injection in dialysis patients with secondary hyperparathyroidism of chronic kidney disease. The pharmacological effects of the drug, pharmacokinetics, clinical trials and adverse reaction profiles.